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Abstract
Background: Failure to adhere to cardiac medications after acute myocardial infarction (AMI) is associated with
increased mortality. Language barriers and preference for traditional medications may predispose certain ethnic
groups at high risk for non-adherence. We compared prescribing and adherence to ACE-inhibitors (ACEI), beta-
blockers (BB), and statins following AMI among elderly Chinese, South Asian, and Non-Asian patients.
Methods: Retrospective-cohort study of elderly AMI survivors (1995-2002) using administrative data from British
Columbia. AMI cases and ethnicity were identified using validated ICD-9/10 coding and surname algorithms,
respectively. Medication adherence was assessed using the ‘proportion of days covered’ (PDC) metric with a PDC
≥ 0.80 indicating optimal adherence. The independent effect of ethnicity on adherence was assessed using
multivariable modeling, adjusting for socio-demographic and clinical characteristics.
Results: There were 9926 elderly AMI survivors (258 Chinese, 511 South Asian patients). More Chinese patients
were prescribed BBs (79.7% vs. 73.1%, p = 0.04) and more South Asian patients were prescribed statins (73.5% vs.
65.2%, p = 0.001). Both Chinese (Odds Ratio [OR] 0.53; 95%CI, 0.39-0.73; p < 0.0001) and South Asian (OR 0.78; 95%
CI, 0.61-0.99; p = 0.04) patients were less adherent to ACEI compared to Non-Asian patients. South Asian patients
were more adherent to BBs (OR 1.3; 95%CI, 1.04-1.62; p = 0.02). There was no difference in prescribing of ACEI, nor
adherence to statins among the ethnicities.
Conclusion: Despite a higher likelihood of being prescribed evidence-based therapies following AMI, Chinese and
South Asian patients were less likely to adhere to ACEI compared to their Non-Asian counterparts.
Keywords: medication adherence, acute myocardial infarction, ethnicity
Background
Acute myocardial infarction (AMI) is one of the leading
causes of death across multiple ethnic groups in North
America. Landmark clinical trials established the efficacy
of medications in reducing morbidity and mortality asso-
ciated with AMI [1-3]. The morbidity and mortality bene-
fits observed in these trials were largely among patients
who were highly adherent. However, in real-world settings,
typical adherence rates for prescribed medications are
50%, and are even lower in developing countries [4,5].
Medication non-adherence is associated with substantial
worsening of disease, increased health care costs, and
death [6-9]. From re-hospitalizations to lost workdays, the
collective economic burden of non-adherence is estimated
to be over $100 billion per year.
Non-adherence is a multidimensional phenomenon,
affected by socio-economic status, health systems, disease
states, pharmacological therapies, and patient beliefs [5].
Whether patient ethnicity plays a role in medication
adherence is unclear [5,10]. To date, the literature yields
variable results [11-14] with little data on medication
adherence in Chinese and South Asian populations, the
largest, and fastest growing, ethnic groups in North
America. Language barriers, mistrust of Western medi-
cine, and preference for traditional therapies could
adversely impact medication adherence in these groups.
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any medium, provided the original work is properly cited.Furthermore, different ethnicities may react differently to
the medications. For example, Asian patients have been
noted to have a greater risk for adverse effects from
ACEI [15]. Therefore, we compared prescribing and
adherence to evidence-based therapies [ACE inhibitors
(ACEI), beta-blockers (BB), and HMG-CoA reductase
inhibitors (statin)] using a large multi-ethnic cohort of
elderly Chinese, South Asian, and Non-Asian survivors of
AMI.
Methods
Our research conformed to the Helsinki Declaration and
to local legislation. Ethics approval was obtained from
The University of British Columbia Providence Health
Care Research Ethics Board.
Data Sources
We used hospital discharge administrative data in Brit-
ish Columbia (BC), Canada to identify index cases of
AMI between April 1
st, 1994 and January 1
st, 2002
(Figure 1). This database contains information on co-
morbid conditions, hospital characteristics, and demo-
graphic data. Since Canada has a universal health insur-
ance system, this data is available for all hospitalized
patients in the province.
Medication prescription (for any of ACEI, BB, or statin)
was determined by linkage to the BC Pharmacare prescrip-
tion database. These medication classes were selected
because of their proven mortality benefit in secondary
prevention of cardiovascular events [1-3,16-19]. The Phar-
macare database contains records of all outpatient pre-
scriptions filled in BC by residents aged 65 years or older
including date of prescription fill and days of medication
supplied. Previous studies demonstrate excellent accuracy
with prescription claims databases [0.7% error rate] [20].
By restricting our analysis to patients aged 66 years and
older, we minimize the effects of patient costs on adher-
ence as these individuals pay a deductible on medications
34,973 AMI cases 
April 1, 1994 – January 1, 2002 
10,089 AMI cohort 
Excluded patients: 
- with an AMI within 1 yr prior to index 
admission 
- less than 65 years old 
- who died within 15 months of index 
admission 
- who were not BC residents 
- with erroneous PHN 
- who did not fill a prescription for ACEI, 
BB, statin, CCB, or diuretic within 3 months 
of discharge from hospital for index 
admission 
Excluded prescription data 
earlier than April 1, 1999 
6,682 Prescribing cohort  9,926 Adherence cohort 
Excluded 
patients with 
< 2 refills 
Figure 1 Patient Flow Diagram. ACEI = angiotensin converting enzyme inhibitor, AMI = acute myocardial infarction, BB = beta-blocker, BC =
British Columbia, CCB = calcium channel blocker, PHN = personal health number, statin = HMG-CoA reductase inhibitor.
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year on January 1
st, 2002. All medication costs above this
deductible are paid by Pharmacare.
Study population
The cohort consisted of patients aged 66 years or older
who were discharged from hospital with a most responsi-
ble diagnosis of AMI. To identify index AMI cases, we
used the International Classification of Diseases (ICD9/
ICD10) coding algorithms for hospital administrative data
[ICD9 410.x; ICD10: I21.x]. These coding algorithms for
AMI have been extensively validated against multi-centre
chart audits [21-23]. We only included patients who sur-
vived at least 1 year and 3 months after the hospital
admission, to allow for a sufficient time period to calculate
medication adherence and excluded non-BC residents.
Identification of ethnicity
Ethnicity is the common and/or inherited traits shared by
people of the same race, ancestry, background and/or cul-
ture [24,25]. As self-reported ethnicity is not available in
administrative databases, we used surname algorithms to
categorize patient ethnicity as Chinese (from China, Tai-
wan or Hong Kong) or South Asian (from Pakistan, India
or Bangladesh). The remaining patients will be referred to
as ‘Non-Asian’ although 7% of this non-Chinese, non-
South Asian group is a visible minority according to the
Canadian Census [26]. To identify patients of Chinese des-
cent, we used Quan’s surname algorithm that has a sensi-
tivity of 78%, a specificity of 99.7% and a positive predictive
value of 81% compared to self-reported ethnicity using the
Canadian Community Health Survey [27]. The Nam Peh-
chan surname algorithm has a 90-94% sensitivity, a 99.4%
specificity and a positive predictive value of 63-96% for
determining South Asian ethnicity [28,29].
Prescribing
Since the Pharmacare database only includes data on pre-
scription medications, we limited our selections to ACEIs,
BBs, statins, calcium-channel blockers (CCB), and diuretics.
Calcium-channel blockers and diuretics were included to
contrast the prescribing of cardiac medications with proven
and non-proven mortality benefit. Angiotensin II receptor
blockers (ARBs) were not included in our analysis as these
agents were not part of post-AMI guidelines during the
study period. We collected data on prescribing, within the
3 months prior to AMI and at 1 year after AMI. Since pre-
scribing patterns change over time, we restricted our col-
lection period to April 1
st,1 9 9 9t oM a r c h3 1
st,2 0 0 3t o
better reflect more recent prescribing practices.
Assessment of adherence
We used the ‘proportion of days covered’ (PDC), a com-
monly used metric for evaluating medication adherence.
The PDC represents the number of days a patient had a
medication available, divided by the days observed [6,30].
Patients had to obtain a supply of medication within 3
months of hospital discharge. We used prescription data
from April 1
st,1 9 9 4t oM a r c h3 1
st,2 0 0 3t oe n s u r ew e
had an adequate sample size. To better reflect long-term
medication adherence, we used an observation period of
1 year after the first-filled prescription [6]. A previous
study of AMI patients demonstrated longer assessments
of adherence were not significantly different from a one-
year measurement [6]. We calculated the PDC for a sin-
gle class of medication, as well as the PDC for any one of
ACEI, BB, or statin prescriptions, since our interest was
in adherence to any or all proven therapies. We defined
adherence as a PDC of ≥ 80%, and suboptimal adherence
as a PDC < 80%. The 80% cut-point is similar to that
used in other medication adherence studies and is asso-
ciated with mortality benefit after AMI compared to
other levels of adherence [6,30].
Other variables
We adjusted for several factors that have previously been
shown to affect medication adherence, including previous
use of the drug and number of medications (see Table 1
for list) [6,30-33]. We also adjusted for the number of
hospital re-admissions within the year post-AMI as this
reflects periods where patients are less likely to fill pre-
scriptions [5,6]. To control for severity of illness on
admission between ethnic groups, we used the clinical
and demographic variables from the validated Ontario
AMI mortality prediction rule [34].
Statistical analysis
Baseline characteristics were compared between ethnic
groups using chi-square testing for categorical variables
and ANOVA for continuous variables. Missing values,
found in measures of socio-economic status quintile (<
4.8%), were excluded from the analysis (see Table 1). Mul-
tivariable logistic regression models, adjusting for age, sex,
residential distance from hospital, income quintile, admis-
sion year, number of baseline medications, number of re-
admissions to hospital, prior use of same medication, and
comorbid conditions from the Ontario AMI prediction
rule, were constructed to examine the independent rela-
tionship between adherence (PDC ≥ 80%) and ethnicity.
Logistic regression model assumptions were satisfied. Sta-
tistical significance was defined as a 2-tailed p < 0.05. All
analyses were performed using SAS statistical software
version 9.1 (SAS Institute Inc, Cary, NC).
Results
Baseline characteristics
Of 9926 patients who met inclusion criteria, 258 (2.6%)
were Chinese, 511 (5.1%) were South Asian, and 9157
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trates baseline socio-demographic and clinical character-
istics between the three ethnic groups. Chinese and
South Asian patients tended to reside in urban areas
and comprised a larger proportion of the lower income
quintiles than Non-Asian patients. There were more
Chinese and South Asian patients with diabetes, conges-
tive heart failure, kidney disease, hypertension, and
more Chinese patients with cerebrovascular disease.
Both Chinese and South Asian patients were prescribed
a greater number of total medications within 3 months
of hospital discharge.
Prescribing of evidence-based therapies
In all ethnic groups, there were significant increases in
prescriptions for evidence-based therapies after dis-
charge from hospital for AMI (Table 2). However,
despite the high risk of re-infarction, 25% of patients did
not fill a prescription for any evidence-based therapies.
Compared to Non-Asian patients, Chinese patients were
more likely prescribed BBs, while South Asian patients
were more likely prescribed statins. There was no signif-
icant difference in ACEI prescribing between the ethnic
groups. There was also no difference in prescribing of
C C B sb e t w e e nt h ee t h n i cg r o u p s .W h i l em o r eN o n -
Asian patients were prescribed diuretics prior to AMI,
there was no difference in diuretic prescriptions between
the ethnic groups post-AMI.
Adherence to evidence-based therapies
The majority (79.9%) of patients were adherent to at least
one of the three evidence-based therapies (Table 3). In
the unadjusted analysis, there was no significant differ-
ence between the ethnic groups for adherence to any one
of ACEI, BB, or statin medication (82.6% South Asian vs.
76.4% Chinese vs. 79.9% Non-Asian patients). Examining
Table 1 Patient characteristics according to ethnicity
Characteristic Chinese South Asian Non-Asian p-value
N = 258 N = 511 N = 9157
Age, n (%)
65-69 years 66 (25.6) 167 (32.7) 2297 (25.1) 0.0006
70-74 years 63 (24.4) 143 (28) 2330 (25.5) 0.40
75-79 years 62 (24) 104 (20.4) 2111 (23.1) 0.34
≥ 80 years 67 (26) 97 (19) 2419 (26.4) 0.001
Female, n (%) 93 (36.1) 204 (39.9) 3718 (40.6) 0.33
Income, n (%) *
< $30,569 83 (32.2) 129 (25.2) 2165 (23.6) < 0.0001
$30,570-43,147 78 (30.2) 138 (27) 1735 (19) < 0.0001
$43,148 - 54,103 36 (14) 110 (21.5) 1642 (17.9) < 0.0001
$54,104 - 68,206 23 (8.9) 62 (12.1) 1609 (17.6) < 0.0001
$68,207 - 221,991 35 (13.6) 55 (10.8) 1559 (17) < 0.0001
> 50km to hospital, n (%) 12 (4.7) 74 (14.5) 3181 (34.7) < 0.0001
Number of hospitalizations, mean (SD) 0.18 (0.49) 0.31 (0.66) 0.3 (0.64) < 0.0001
Total # of medications
†, mean (SD) 7.51 (3.81) 8.18 (3.9) 7.32 (3.63) 0.011
Prior use of ACEI, BB, or statin
‡, n (%) 109 (42.3) 188 (36.8) 3376 (36.9) 0.21
Comorbidities, n (%)
Diabetes 67 (26) 152 (29.8) 1526 (16.7) < 0.0001
CHF 58 (22.5) 110 (21.5) 1570 (17.2) 0.004
Cardiac 40 (15.5) 60 (11.7) 1392 (15.2) 0.10
PAD 7 (2.7) 4 (0.8) 342 (3.7) 0.0016
Hypertension 98 (38) 160 (31.3) 2402 (26.2) < 0.0001
Cerebrovascular 12 (4.7) 9 (1.8) 203 (2.2) 0.03
Kidney disease 15 (5.8) 16 (3.1) 180 (2) < 0.0001
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; BB = beta-blocker; CHF = congestive heart failure; PAD = peripheral arterial disease; PDC =
proportion of days covered.
* Missing socio-economic status data was < 4.8% (1.6% Chinese, 3.4% South Asians, 4.9% Non-Asians).
† Within 3 months of discharge from index admission date.
‡ Within 3 months prior to index admission date.
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proportion of Chinese patients adhering to ACEI and a
larger proportion of South Asian patients adhering to
BBs relative to Non-Asian patients. Adherence to statins
was similar across all ethnic groups. Adherence to CCBs
and diuretics was also similar across all ethnicities,
although adherence rates for diuretics were low in all
groups.
In the adjusted analysis, Chinese patients were less
likely to adhere to ACEI, compared to Non-Asians, [OR
0.53; 95%CI: 0.39-0.73]. Chinese patients, overall, were
also less likely to be adherent to any of ACEI, BB, or
statin medication [OR 0.70; 95%CI: 0.51-0.95]. Com-
pared to Non-Asians, South Asians were less likely to be
adherent to ACEI [OR 0.78; 95%CI: 0.61-0.99] but more
likely to be adherent to BBs [OR 1.3; 95%CI: 1.04-1.62].
Among the medications with less evidence for cardio-
protection, there was no significant difference in adher-
ence to CCBs, but South Asian patients were less likely
to adhere to diuretics compared to Non-Asian patients.
Discussion
In this study, elderly Chinese and South Asian patients
were as or more likely to be prescribed evidence-based
therapies following AMI compared to their Non-Asian
counterparts. However, adherence varied by medication
class in the ethnic groups.
Overall prescribing rates for secondary prevention of
AMI were poor for statin medications (68%) but higher
for ACEI and BB medications (77-78%). Overall prescrib-
ing of these medications was similar to those in other
studies [6,35]. Appropriately, we saw a decrease in pre-
scribing for CCBs. We foundt h a tC h i n e s ea n dS o u t h
Asian patients were more likely to be prescribed BBs and
statins compared to Non-Asian patients. Reasons for this
are unclear; prescribing physicians may consider Chinese
and South Asian patients to be at higher cardiac risk,
necessitating more aggressive management. Studies
demonstrate that South Asian patients, for example, are
more or just as likely to receive invasive cardiovascular
procedures following AMI, compared to their Non-Asian
counterparts [36]. Alternatively, Chinese and South
Asian patients may have been more likely to fill their pre-
scriptions once discharged from hospital compared to
Non-Asian patients. Non-Asian patients tended to reside
outside of urban areas where access to medical follow-up
was perhaps more limited, potentially resulting in fewer
opportunities to fill prescriptions.
This study found that elderly Chinese patients were less
likely to adhere to any evidence based therapy following
Table 3 Adherence to cardiac medications (PDC ≥ 80%) according to ethnicity and medication
Medication Chinese South Asian Non-Asian p-value Adj. OR (95%CI)* Adj. OR (95%CI)*
Chinese vs. Non-Asian p-value South Asian vs. Non-Asian p-value
ACEI, % 63.5 71.4 75 < 0.001 0.53 (0.39-0.73) < 0.001 0.78 (0.61-0.99) 0.04
BB, % 54.1 63.4 56.4 0.02 0.85 (0.63-1.15) 0.29 1.3 (1.04-1.62) 0.02
Statin, % 80.8 85.4 81 0.19 0.83 (0.52-1.35) 0.46 1.26 (0.88-1.79) 0.21
CCB, % 64 68.4 65.5 0.73 0.84 (0.51-1.38) 0.49 1.07 (0.74-1.53) 0.73
Diuretic, % 35.9 33.8 39.5 0.18 0.84 (0.55-1.28) 0.41 0.73 (0.54-0.99) 0.04
ACEI, BB, or statin, % 76.4 82.6 79.9 0.12 0.70 (0.51-0.95) 0.02 1.01 (0.79-1.29) 0.92
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; Adj. OR = adjusted odds ratio; BB = beta-blocker; CCB = calcium-channel blocker; PDC =
proportion of days covered
* odds ratios adjusted for age, gender, residential distance from hospital, socio-economic status, admission year, number of baseline medications, number of
re-admissions to hospital, prior use of same medication, and comorbidities
Table 2 Medication prescribing according to ethnicity 3 months prior to AMI and 1 year post AMI, n (%)
Medication 3 months prior to AMI 1 year post AMI
Chinese
(n = 150)
South Asian
(n = 224)
Non-Asian
(n = 3697)
p-value Chinese
(n = 197)
South Asian
(n = 370)
Non-Asian
(n = 6115)
p-value
ACEI 66 (44) 86 (38.4) 1586 (42.9) 0.39 157 (79.7) 293 (79.2) 4621 (75.6) 0.13
BB 56 (37.3) 66 (29.5) 1134 (30.7) 0.2 157 (79.7) 286 (77.3) 4472 (73.1) 0.03*
Statin 40 (26.7) 69 (30.8) 973 (26.3) 0.34 132 (67) 272 (73.5) 3987 (65.2) 0.004
†
ACEI, BB, or Statin 110 (73.3) 154 (68.8) 2641 (71.4) 0.59 194 (98.5) 360 (97.3) 5867 (95.9) 0.09
CCB 61 (40.7) 84 (37.5) 1312 (35.5) 0.37 66 (33.5) 131 (35.4) 1856 (30.4) 0.09
Diuretic 42 (28) 76 (33.9) 1568 (42.4) < 0.001 104 (52.8) 189 (51.2) 2990 (48.9) 0.42
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; AMI = acute myocardial infarction; BB = beta-blocker; CCB = calcium-channel blocker.
* For BBs: Chinese vs. Non-Asian, p = 0.04; South Asian vs. Non-Asian, p = 0.08.
† For statins: Chinese vs. Non-Asian, p = 0.6; South Asian vs. Non-Asian, p = 0.001.
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this is the first study evaluating the adherence to second-
ary prevention medications following AMI in Chinese
and South Asian patients. In addition to the factors asso-
ciated with non-adherence found in the general popula-
tion, non-adherence in these ethnic populations may be
further amplified by language barriers [37-40] and differ-
ences in health literacy [40-42] among ethnocultural
groups. Furthermore, ethnocultural patients may have a
preference for alternative or natural therapies [43-45],
and some may perceive that antihypertensive therapy is
not beneficial [46]. Furthermore, differences in health
beliefs and strong Eastern views of care (e.g. viewing dis-
ease as a result of fate and avoidance of medical visits)
are associated with poor adherence to treatment recom-
mendations [47]. Intriguingly, even within the same class
of medication, we found that adherence varied by patient
ethnicity with the greatest proportion of suboptimal
adherence for ACEI in both Chinese and South Asian
patients. This observation raises suspicion that the differ-
ences in adherence may be, at least in part, attributed to
greater adverse effect profiles within these ethnic groups.
In a systematic review of cardiovascular drug utilization,
ACEI-induced cough was more prevalent in Asian
patients than in the general population, although South
Asian patients were not studied separately [15]. Adher-
ence to statins was similar across ethnic groups despite
the fact that, in post-marketing surveillance, rosuvastatin
was associated with greater statin-induced myopathy in
Asian patients [48].
This study had several limitations. First, we only used a
proxy measurement for adherence using prescriptions
claims data. Although this approach does not ensure that
the medications were ingested, prescription claims data
highly correlates with home inventory pill counts, as well
as serum measures of drug presence [49-51]. As with all
observational studies, we were limited by residual con-
founders since we were unable to assess other factors
associated with non-adherence such as dementia and
depression. Similarly, we did not have access to other
clinical information such as left ventricular function
or creatinine, but we attempted to adjust for some of
the clinical variables by including the diagnosis of CHF
or kidney disease, for example, in Table 1. We did not
include Angiotensin receptor blockers (ARBs) in our ana-
l y s i s .T h e s ea g e n t sh a v eb e c o m em o r ew i d e l yu s e ds i n c e
the study period, and are often prescribed for patients
who experience negative side effects from ACEI, thereby
potentially impacting adherence to any renin-angioten-
sin-aldosterone agent (either ACEI or ARBs). Finally, we
investigated medication adherence among major ethnic
groups in Canada who were elderly; these results may
not be generalized to other ethnic groups or to younger
patients within these groups.
Conclusions
Compared to their Non-Asian counterparts, South Asian
and Chinese elderly patients are just as likely or more
likely to receive proven secondary prevention therapies.
However, in this cohort of high cardiac risk patients, 25%
of patients did not fill a prescription for these therapies,
suggesting greater need to improve prescribing in all eth-
nic groups following AMI. Chinese patients were less
likely to be adherent to any secondary prevention medica-
tion and specifically, ACEI therapy. South Asian patients
were also less likely to be adherent to ACEI therapy rela-
tive to their Non-Asian counterparts. This study identifies
an at-risk group of patients that require aggressive moni-
toring, follow-up and support to optimize adherence.
Future studies evaluating underlying cultural barriers to
adherence are needed to develop culturally-tailored inter-
ventions to improve adherence. The disproportionately
lower adherence to ACEI in South Asian and Chinese
patients, raises suspicion that both of these groups may
suffer greater adverse effects associated with ACEI.
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